, Volume 10, Issue 1, pp 19–28

Natalizumab Therapy for Multiple Sclerosis


DOI: 10.1007/s13311-012-0171-4

Cite this article as:
Chataway, J. & Miller, D.H. Neurotherapeutics (2013) 10: 19. doi:10.1007/s13311-012-0171-4


The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.


NatalizumabRelapsing remitting MSProgressive multifocal leucoencephalopathy

Supplementary material

13311_2012_171_MOESM1_ESM.pdf (511 kb)
ESM 1(PDF 510 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2013

Authors and Affiliations

  1. 1.Queen Square Multiple Sclerosis Centre, National Hospital for Neurology & Neurosurgery and University College London Institute of NeurologyLondonUK